ObjectivesWe report on a patient with a distinct clinical and neuroradiologic phenotype and a de novo variant in the FTH1 gene. MethodsThe patient was a 25-year-old woman with developmental delay and pontocerebellar hypoplasia, who after years of stable condition visited our hospital at age 20 years because of clinical deterioration. With consent from the patients’ family, we obtained clinical, imaging, and genetic data from the patient’s medical record.
Microglial replacement strategy to treat microgliopathy.
Colony-stimulating factor 1 receptor (CSF1R) gene mutation (I794T) is linked to primary microgliopathy manifesting as leukoencephalopathy.
The researchers define the clinical features of patients carrying the CSF1R p. I794T variant and establish a corresponding knockin mouse model.
The authors demonstrate that knockin mice exhibited hallmark features of CSF1R-related disorder (CSF1R-RD).
They show that Csf1rI792T/+ microglia adopt a disease associated state and that a microglial replacement strategy termed “duplicate-cyclic microglial depletion for transplantation” (DCMDT), mitigates cognitive and neuropathological deficits in CSF1R-RD. sciencenewshighlights ScienceMission https://sciencemission.com/microglia-replacement-18450
Li et al. define the clinical features of patients carrying the CSF1R p. I794T variant and establish a corresponding knockin mouse model. They show that Csf1rI792T/+ microglia adopt a disease-associated state and that a microglial replacement strategy, DCMDT, mitigates cognitive and neuropathological deficits in CSF1R-related disorder.
Researchers at the Cancer Research Institute and the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have uncovered a critical mechanism that enables gastric cancer to spread to distant organs. Their study shows that cancer cells stimulate Wnt signaling in surrounding stromal fibroblasts to produce hyaluronan, creating a supportive microenvironment that promotes metastasis. These findings provide new insight into how metastatic tumors establish themselves and suggest promising strategies to prevent gastric cancer progression. The work is published in the journal Nature Communications.
Gastric cancer remains one of the leading causes of cancer-related deaths worldwide, largely because it frequently spreads to other organs such as the liver. While genetic mutations that initiate tumors have been extensively studied, the biological mechanisms that allow cancer cells to colonize new tissues remain poorly understood.
“Wnt signaling”—a pathway essential for stem cell maintenance and tissue regeneration—is often activated in gastric cancer through external ligand stimulation rather than genetic mutation. This study further identifies that Wnt signaling in the tumor microenvironment also plays a crucial role in disease progression.
A wealthy family fighting its own disease boosted research on a little-studied brain protein, progranulin. Can it spur new dementia treatments?
Bluefield investigators, and eventually drug companies, saw something compelling about FTD-GRN, the form of the condition Alice had. In other genetic neurodegenerative disorders, such as familial Alzheimer’s and Huntington disease, mutations spark the production of toxic proteins, generating complex cascades of pathology. But the culprit mutations driving FTD-GRN block progranulin production, leaving carriers with less than half as much of the protein as noncarriers. Many dementia researchers came to describe FTD-GRN as a “low-hanging fruit” among neurodegenerative diseases, using words such as “intuitive” and “tractable” to characterize its biology. The solution seemed obvious: A treatment just needed to raise progranulin levels in the brain.
Fueled in part by that confidence, six clinical trials have been launched to test progranulin-boosting therapies in FTD-GRN. Companies also hope the anti-inflammatory properties of a progranulin-boosting agent could help in Parkinson’s disease, Alzheimer’s, amyotrophic lateral sclerosis (ALS), and FTD caused by other mutations or without a known genetic cause.
All has not gone according to plan, however. In October 2025, a landmark phase 3 clinical trial of a progranulin-boosting drug in people with FTD-GRN did not keep their disease from progressing. In February, a small trial of a gene therapy delivering a healthy copy of GRN to the brain was halted, also for lack of effect.
Researchers at Washington University in St. Louis have developed a novel cell therapy for Alzheimer’s disease using genetically modified astrocytes — the brain’s most abundant cells. By equipping these cells with a chimeric antigen receptor (CAR), scientists enabled them to specifically target and clear beta-amyloid plaques, the toxic protein deposits that accumulate in brain tissue and drive neurodegeneration. In mouse trials, a single injection prevented plaque formation in young healthy rodents and reduced existing plaque levels by half in older mice. While the approach is still being refined to minimize side effects and must be evaluated for human safety, it holds promise both as a preventive measure and as a treatment at various stages of Alzheimer’s. The same technology may eventually be adapted for cancer therapy by reprogramming the cells to target tumor markers.
Alzheimer’s disease (AD) is the leading cause of dementia and is characterized by progressive amyloid accumulation followed by tau-mediated neurodegeneration. Despite advances in anti-amyloid immunotherapies, important limitations remain, highlighting the need for new therapeutic strategies. Here, we introduce anti-amyloid chimeric antigen receptors expressed in astrocytes (CAR-A) and validate their function in vitro. We show that two CAR-A designs reduce amyloid and associated pathology after plaque formation and prevent early plaque deposition in vivo. Single-nucleus RNA sequencing shows that CAR-A treatment induces a distinct glial response to amyloid pathology involving coordinated activity of astrocytes and microglia. Each construct additionally elicits distinctive, receptor-specific effects in astrocytes or microglia.
Solid tumor antigen heterogeneity is a major challenge for cancer immunotherapies, including chimeric antigen receptor (CAR) T cells. Unlike CD19 for B cell malignancies, no target with pan-cellular expression in solid tumors and absence in normal vital cells has been identified. CD70 is a promising candidate, physiologically confined to immune cell subsets and aberrantly expressed in many cancers. We show that heterogeneous CD70 expression in tumors is epigenetically regulated, ranging from high to very low in individual cells, appearing negative by conventional detection methods. Using a highly sensitive CD70 receptor, HLA-independent T cell (HIT) receptor coexpressing CD80 and 4-1BBL for costimulation, we efficiently eliminated CD70-heterogeneous tumors that evade prototypic CAR T cells. These findings provide a potential strategy to treat a broad range of solid tumors.
Protein activity can be precisely regulated via subtle changes in temperature using heat-sensitive switches. Underlying this capability is a novel modular design strategy developed by researchers at the Institute of Pharmacy and Molecular Biotechnology of Heidelberg University. The strategy allows the integration of sensory domains in various proteins regardless of function or spatial structure.
This new approach in the field of thermogenetics is broadly applicable and opens up new possibilities for precise, non-invasive control of different cellular processes. It was developed by a research team led by Prof. Dr. Dominik Niopek and Dr. Jan Mathony and is published in Nature Chemical Biology
Proteins are the molecular machines of the cell. They regulate nearly all vital processes and their responses are highly dynamic. To better understand these processes and their chronological sequence, scientists need tools that can be used to change individual parameters precisely and in a controlled manner. The most suitable proteins are those that can be turned on and off like technical devices. Especially attractive in this context are heat-sensitive protein switches that tightly regulate the temperature spatiotemporally and are able to deeply penetrate tissue or complex biological samples as a signal.
Excellent Substack writeup by Patrick Mineault on how cell types may specify innate behaviors and why mapping regions of the brain specialized to steer innate behaviors (via lots of distinct cell types) could lead us to more aligned AI systems. Highly convincing and elegant arguments made here! [ https://substack.com/home/post/p-189321289](https://substack.com/home/post/p-189321289)
Dwarkesh seemed very confused by this, asking a few different times: “Why would each reward function need a different cell type?” I empathize with Dwarkesh here! It is mysterious that a cell type could represent something as abstract as a reward. As a computational neuroscientist who mostly worked at the representation level during my PhD, I’ve leaned historically towards thinking of cell types as a mere “implementation detail”. But over conversations with Adam, Steve Byrnes, Paul Cisek, Tony Zador, and a few others, I’ve started to become convinced that cell types are a really useful lens to think about innate behaviors and rewards.
In this essay, I’ll unpack the conversation and answer the question: what do cell types have to do with reward functions? To answer it, we’ll need to understand what kind of information can be encoded in the genome, and how that information ultimately relates to connectomes and to cell types. I’ll connect the answer to the central claim of Adam: that these connections matter for AI, and AI safety in particular.
Andrew Barto and colleagues make the point that all primary rewards are internal, and must be genetically encoded. In reinforcement learning, which Barto co-developed along with Rich Sutton, an agent learns by receiving reward signals that indicate what is good and bad. The critical insight is that for biological organisms, all of these reward signals are internal —they are generated by the organism’s own nervous system. It is not a chunk of steak that gives reward: it is circuitry inside the brain that assigns positive valence to fat, salt, umami, heat, and texture. Things like money—secondary rewards—must be bootstrapped off of the pre-existing primary rewards.
Neurodevelopmental disorders from Polycomb complex missense mutations.
The causes of many neurodevelopmental disorders (NDDs) is yet to be determined.
The researchers report new missense mutations in the Polycomb repressive complex 1 (PRC1) E3 ligases RNF2 and RING1 in individuals with neurodevelopmental disorders.
Functional dissection of a deleterious variant reveals that balanced co-recruitment of Polycomb complexes to chromatin is essential for proper neurogenesis and for normal brain function and behavior. sciencenewshighlights ScienceMission https://sciencemission.com/Polycomb-complexes-drives-NDDs
Borges, González-Blanco, Arigela, et al. report new missense mutations in the PRC1 genes RNF2 and RING1 in individuals with neurodevelopmental disorders. Functional dissection of a deleterious variant reveals that balanced co-recruitment of Polycomb complexes to chromatin is essential for proper neurogenesis and for normal brain function and behavior.